Introduction
============

Focal segmental glomerulosclerosis (FSGS) is a description of a histological lesion, rather than a disease; characterized by focal and segmental glomerular sclerosis and podocyte foot-process effacement and its clinical manifestations include proteinuria and progressive renal failure. Current treatments for FSGS frequently fail to achieve remission ([@b1-mmr-17-01-1513],[@b2-mmr-17-01-1513]). Therefore, unravelling the pathogenesis of FSGS is of primary concern for the development of targeted therapy.

The etiology of FSGS has been identified as diverse. FSGS may occur following immunologically-mediated injury, genetic factors, circulating permeability factor/s, and hemodynamic adaptations resulting in glomerular hypertrophy and direct podocyte injury also lead to FSGS ([@b3-mmr-17-01-1513]). The most common clinical manifestation of FSGS is proteinuria, which may range from subnephrotic to nephrotic levels. However, a number of the patients with proven-FSGS present with hematuria ([@b4-mmr-17-01-1513]).

The renal glomerular filtering apparatus consists of three major components: The fenestrated endothelial cell layer, the glomerular basement membrane (GBM) and the epithelial podocyte layer. Injury to any layer may result in red blood cells or protein escaping into the urine through a defect in the glomerular filtration barrier. It has been demonstrated that podocyte damage serves a central role in the pathogenesis of FSGS ([@b5-mmr-17-01-1513],[@b6-mmr-17-01-1513]). A number of genes have also been demonstrated to be mutated in FSGS ([@b7-mmr-17-01-1513]--[@b24-mmr-17-01-1513]) ([Table I](#tI-mmr-17-01-1513){ref-type="table"}), and most of the encoded proteins are localized in podocytes, whereas others are expressed in other tissues and cell types including in GBM ([@b20-mmr-17-01-1513]--[@b22-mmr-17-01-1513],[@b25-mmr-17-01-1513]--[@b26-mmr-17-01-1513]). According to statistical analysis, 1/3-1/2 of children with isolated, persistent hematuria have a familial history ([@b27-mmr-17-01-1513]--[@b28-mmr-17-01-1513]). It has been demonstrated by previous studies that long-term persistent microscopic hematuria (MH) may lead to chronic kidney disease (CKD) ([@b29-mmr-17-01-1513]--[@b32-mmr-17-01-1513]). A total of \~14--50% of familial cases progress to end-stage renal disease (ESRD) on long-term follow-ups ([@b33-mmr-17-01-1513]).

Alport\'s Syndrome (AS) and thin basement membrane neuropathy (TBMN), which occur most frequently in glomerular MH, result from defects in type IV collagen. The type IV collagen α3α4α5 chain is a major component of the GBM and a heterotrimer that is encoded by three genes: Collagen type IV α 3 chain (COL4A3), COL4A4 and COL4A5 ([@b34-mmr-17-01-1513]). During the last three decades, six genes (COL4A3, COL4A4, COL4A5, complement factor H related 5, myosin heavy chain 9 and fibronectin 1) have so far been identified in familial microscopic hematuria of glomerular origin ([@b34-mmr-17-01-1513]). In addition to AS and TBMN, familial FSGS may also be a factor resulting in familial glomerular microscopic hematuria (GMH) ([@b4-mmr-17-01-1513]).

It has been demonstrated by previous studies that long-term persistent MH may lead to renal injury regardless of TBMN, AS or other disease presenting with hematuria ([@b29-mmr-17-01-1513]--[@b32-mmr-17-01-1513]). Therefore, pediatric nephrologists need to be aware that children with familial hematuria and a family history of CKD have a high probability of developing proteinuria and progressing to renal failure in adult life. Especially at early stages when MH appears as an isolated warning sign, it is worth having a step-wise algorithm for deeper investigations of the etiology and pathogenesis of the disease.

Advances in DNA analysis technology may facilitate greater use of molecular diagnostics, which reduce the need to use invasive methods including renal biopsy ([@b4-mmr-17-01-1513]). Importantly, molecular diagnostics may be performed at an early stage of disease, frequently providing a broader set of therapeutic options and an increased window of opportunity to ameliorate disease progression ([@b35-mmr-17-01-1513]).

Recently the implementation of high-throughput sequencing technologies including mass array technology and whole exome sequencing (WES) make it possible to test multiple genes simultaneously in a single experiment faster and more efficiently ([@b36-mmr-17-01-1513]). The performance of the next-generation sequencing may help to identify novel genes or novel unreported mutations and discover co-segregating genetic regions. However, the appropriate application and combination of sequencing methods with conventional gene-discovery strategies should be considered for each patient and research project ([@b36-mmr-17-01-1513]). Only then may they be of use in making a diagnosis in a more precise way.

The present study reports on a family in which affected individuals exhibited familial hematuria and the siblings had biopsy-proven FSGS and normal GBM. Renal biopsies demonstrated non-specific pathological alterations and failed to exhibit glomerular or basement membrane defects consistent with an inherited glomerulopathy, and therefore a possible underlying genetic cause for a unifying and definitive diagnosis was pursued. The present study hypothesized that FSGS in the siblings resulted from a defect in the 18 genes \[*nephrin (NPHS1), podocin (NPHS2), CD2 associated protein (CD2AP)*, *phospholipase C ε (PLCE1)*, *actinin α 4 (ACTN4)*, *transient receptor potential cation channel subfamily C member 6, (TRPC6)*, *inverted formin, FH2 and WH2 domain containing (INF2)*, *Wilms tumor 1 (WT1)*, *LIM homeobox transcription factor 1β (βLMX1B), laminin subunit β (LAMB) 2*, *LAMB3*, *galactosidase α*, *integrin subunit β 4, scavenger receptor class B member 2* (*SCARB2)*, *coenzyme Q2 (COQ2)*, *decaprenyl diphosphate synthase subunit 2 (PDSS2)*, *mitochondrially encoded tRNA leucine 1* (UUA/G; *TRNL1)* and *SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1*\]. Under this assumption, the siblings were identified as possessing a homozygous mutation for TRNL1 (m. 3290T\>C), which may segregate with disease using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry technology. WES on the siblings was performed to identify the existence of other genes or mutations that co-segregate with familial hematuria or FSGS when mutated. The results demonstrated that the two sisters carried a single heterozygous mutation c. A4195T (p. M1399L) in the COL4A4 gene, which may serve a role in the pathology of FSGS and act as a modifier to TRNL1.

To the best of the authors\' knowledge, this is the first report of a family with familial hematuria and proven-FSGS with a mutation in the TRNL1 gene, and with a mutation in the COL4A4 gene that co-segregated with disease. In addition, this may be the first study to use mass array technology and WES simultaneously in the identification of disease genes.

Materials and methods
=====================

### Clinical data and DNA preparation

Clinical data and historical renal biopsies were reviewed where available. Following informed consent being obtained, DNA was obtained from the siblings (1\~14 years old) and their father (33--34 years old; data not available from their mother) obtained from the Second Xiangya Hospital during the period March/2014-March/2015. The research was approved by the Ethics Commission of the Second Xiangya Hospital (Changsa, China). DNA was isolated from peripheral leukocytes using the DNA purification kit (Tiangen Biotech Co., Ltd., Beijing, China) according to the manufacturer\'s protocol.

### Single nucleotide polymorphism (SNP) analysis using MALDI-TOF technology

The genes and SNPs were selected on the basis of currently available literature ([@b22-mmr-17-01-1513]). The 15 genes were selected following searching databases including PubMed, the Online Mendelian Inheritance in Man (OMIM; [www.ncbi.nlm.nih.gov/omim](www.ncbi.nlm.nih.gov/omim)) and the Human Gene Mutation Database ([nihlibrary.nih.gov/about-us/news/categories/3051](nihlibrary.nih.gov/about-us/news/categories/3051)). Database ClinVar and OMIM were searched for clinically relevant mutations or SNPs from the 18 genes. The database search identified 179 candidates. Certain candidates either lacked complete information or were not compatible for MassArray technology. A total of 138 mutations were included in the assay.

### Polymerase chain reaction (PCR)

The assay was designed using MassARRAY^®^ software (version 4.0; Sequenom, San Diego, CA, USA). The 138 mutations were assigned to six multiplex assays. PCR primers were designed using Mass ARRAY^®^ Assay Design 4.0 Software (Sequenom) ([Table II](#tII-mmr-17-01-1513){ref-type="table"}). PCR was first performed using the following protocol: 4 min at 95°C for activation of Faststart taq DNA polymerase (Roche Diagnostics, Basel, Switzerland, cat. no. 12032937001) and 30 sec at 95°C, 30 sec at 56°C, 1 min at 72°C for 45 cycles, followed by 5 min at 72°C. The PCR products were subjected to shrimp alkaline phosphatase (SAP) reaction for the degradation of residual dNTPs. The SAP reaction was performed as follows: 40 min at 37°C and 5 min at 85°C. Following this, extension reaction was performed by the following protocol: 30 sec at 94°C, 40 cycles for 5 sec at 94°C, from 5 sec at 52°C to 5 sec at 80°C for 5 cycles, and finally 3 min at 72°C. Then, the products were desalted using resin. The final products were analyzed by MALDI-TOF mass spectrometry (Mass ARRAY^®^ Typer 4.0.5 Software, Sequenom) to identify the mass. SNP genotyping was performed on SEQUENOM^®^MassARRAY^®^ platform using the iPLEX^™^ assay (Sequenom) ([@b37-mmr-17-01-1513]).

### WES analysis

WES was performed on the two siblings. A total of 6 µg sample DNA was prepared. First, the qualified DNA samples were randomly fragmented to generate 200--300 bp DNA fragments. The extracted DNA was amplified in a ligation-mediated (LM)-PCR, as described earlier. The NimbleGen human exome array (SeqCap EZ Human Exome Library; version 2.0; NimbleGen, Roche Diagnostics cat. no. 06465684001 or 06465692001) was used to capture the exons of the human genome. High-throughput sequencing was performed on a Hiseq2000 platform (Illumina), and the sequence of each library was generated as 90 bp paired-end reads. The raw image files were processed by Illumina base calling Software (Illumina Inc. San Diego, CA, USA, version 1.7; HCS1.5.15.1, RTA1.13.48, OLB 1.9.4). The obtained sequences were aligned to the reference genome \[human genome build37 (hg19)\] using Burrows-Wheeler Aligner (BWA; [bio-bwa.sourceforge.net/](bio-bwa.sourceforge.net/); version: 0.5.9-r16). Single-nucleotide polymorphisms (SNPs) were detected by SOAPsnp (<http://soap.genomics.org.cn/soapsnp.html>; version 1.05) and small insertions/deletions (indels) were detected by SAMtools (version: 0.1.18; [www.htslib.org/](www.htslib.org/)). Called SNP variants and indels were annotated and classified using ANNOVAR ([www.ncbi.nlm.nih.gov/pmc/articles/PMC2938201/](www.ncbi.nlm.nih.gov/pmc/articles/PMC2938201/)). Variants were filtered using data from dbSNP 142 and the 1000 Genomes Project.

### Pathological diagnosis

The renal tissue was fixed in 10% neutral buffered formalin and stored at room temperature or 4°C. The fixed tissue was embedded in paraffin and 2-µm sections were cut. HE, PAS, PASM+Masson and Masson staining were performed at 37°C as described previously ([@b22-mmr-17-01-1513]).

### In silico analyses of the effect on protein structure and function

Selected bioinformatics tools were used to assess the effect of sequence variants on the structure and function of the receptor. A total of two indirect *in silico* predictors, PolyPhen2 (Polymorphism Phenotyping version 2; [genetics.bwh.harvard.edu/pph2/index.shtml](genetics.bwh.harvard.edu/pph2/index.shtml)) and SIFT ([sift.jcvi.org](sift.jcvi.org)), were used to evaluate the possibly damaging effects of single amino-acid substitutions on the expression of the proteins of these genes. To identify potential pathogenic mutations, additional analysis focused on the variants that are listed in OMIM as being associated with FSGS (even if frequent) and also any other indels and nonsense variants. For the missense variants, the high risk variants were determined by a minor allele frequency (MAF) of 1% or unknown (using 1,000 Genomes population data; [www.1000genomes.org/node/506](www.1000genomes.org/node/506)).

Results
=======

### Quality control

Mass array technology assigns a quality code for each genotyping call. Codes A, B, C, D and I stand for conservative, moderate, aggressive, low possibility and bad spectrum, respectively. The lower the order of the code from A to Z, the higher the quality of the genotyping calls. Code A indicates the highest quality and code D and I indicate no genotyping call (reported as NA). The overall quality of the assay is summarized in [Table III](#tIII-mmr-17-01-1513){ref-type="table"}. The total number of genotyping calls are 5,658, which is a product of 138 (the number of variations) and 41 (the number of samples). The percentage of code A calls is 90. 84% and the sum of code A, code B and code C calls is 98.09%. Overall, the assay achieved a good quality. The assay quality was also investigated to see the distribution of no call genotypes (quality code D and I) among the mutations identified. Two variations (rs121912601, rs2717-192514) did not get genotypes from \>10% samples and genotyping of 4 variations (rs121918230, rs121907911, rs28935487, rs267607183) failed in \>20% samples. As the Mass array genotyping assay is multiplexed, these mutations/SNPs are likely to be susceptible to assay condition variations. The performance of the assay may be improved by redesigning the PCR primers and extension primers for these variations.

The two affected sisters were selected for exome sequencing. For each participant, 4,4017,835 bases were created and covered on the target. The sequence data were generated with a ×177 average coverage for each subject. An average coverage of the target region was 98.96 and 99.27% of the target region had at least ×4 coverage. For each participant, 21,134 single-nucleotide variants were identified, of which 9,986 were missense mutations and 135 were nonsense (premature termination) mutations.

### Clinical characteristics

A total of two female siblings presented with MH at 9 and 6 years-old, respectively. The oldest sibling was referred to the Second Xiangya Hospital for persistent MH (8 months) with macroscopic hematuria initially. The physical examination revealed no abnormalities and the older sibling did not suffer from hypertension, sensorineural deafness, or eye involvement. Laboratory tests revealed only MH, which was demonstrated to be glomerular hematuria by the urinary sediment test (erythrocytes 100,000/high power field; 70% of glomeruli; urinary protein 0 mg/dl), with normal renal function. Values obtained in the hematological, biochemical and serological tests were: Serum creatinine, 26.8 µmol/l; hemoglobin, 111 g/l; total protein, 61.5 g/l; uric acid, 83.6 µ/l; cholesterol, 3.5 µmol/l; complement component, 31.16 g/l and blood urea nitrogen 4.58 µmol/l.

A renal biopsy was performed in hospital and this demonstrated severe glomerular alterations consistent with FSGS ([Fig. 1](#f1-mmr-17-01-1513){ref-type="fig"}). Due to continuous MH and positive family history with renal disease, a renal biopsy was performed at the Second Xiangya Hospital. On light microscopy, characteristic lesions of focal glomerulosclerosis were present in 2 of 28 glomeruli ([Fig. 1A](#f1-mmr-17-01-1513){ref-type="fig"}). Sclerotic glomeruli were present in 1 of 28 glomeruli and small arteries exhibited loss of smooth muscle fibers. ([Fig. 1B](#f1-mmr-17-01-1513){ref-type="fig"}). There was mild mesangial matrix proliferation. Vacuolation of the tubular epithelial cells, loss of the brush border of lumen surface and inflammatory cell infiltration was observed ([Fig. 1C](#f1-mmr-17-01-1513){ref-type="fig"}). Mitochondria in podocytes demonstrated normal morphology (original magnification, ×10,000; data not shown). On immunofluorescence, focal segmental coarse granular deposits of immunoglobulin G(+) and proliferation of endothelial cells were observed. Electron microscopy exhibited diffuse podocytic foot process effacement ([Fig. 1D](#f1-mmr-17-01-1513){ref-type="fig"}). The endothelium was swollen and hypertrophied, however the GBM exhibited a normal structure and thickness. Paramesangial deposits were noted. Massive tubules with swollen tubular epithelial cells, edema in the interstitium and inflammatory cell infiltration were noted (data not shown).

The patient was born following a full-term normal pregnancy as the first child of unrelated Chinese parents. The family history was remarkable in that multiple family members were affected by isolated MH or other renal disease in her father\'s pedigree ([Fig. 2](#f2-mmr-17-01-1513){ref-type="fig"}). The family history revealed that the parents were Chinese in origin and non-consanguineous. Her sister was also identified as being affected by isolated MH, histologically characterized as FSGS. Her father was diagnosed with CKD by qualified doctors 8 years ago, in another hospital. Her paternal aunts and paternal cousins have also been identified as exhibiting hematuria. Urinalyses and blood chemistries identified isolated MH. None of the affected individuals had ESRD, sensorineural hearing loss, or eye complications including lenticonus. Their mother was well and was not known to have any kidney disease.

### Variants of TRNL1 in the family

Using Massarray technology, the same mutation in TRNL1 (m. 3290T\>C) was identified in the two sisters, which was not demonstrated by polyphen-2 and SIFT. However, it was predicted to be a pathogenic alteration based on OMIM and Pubmed. This mutation mtT3290C was first detected by Opdal *et al* ([@b38-mmr-17-01-1513]) in 1 of the sudden infant death syndrome (SIDS) cases and it suggested that mutations in mitochondrial DNA (mtDNA) may serve a role in certain cases of SIDS. It was speculated that mtT3290C may segregate with FSGS ([@b38-mmr-17-01-1513]). The results are exhibited in [Fig. 3](#f3-mmr-17-01-1513){ref-type="fig"}. No significant sequence mutations were observed in the other 17 genes analyzed.

### Variants of COL4A3 in two sisters with familial FSGS

WES was performed on the proband and her sister, and this identified a heterozygous candidate COL4A4 missense mutation c. 4195A\>T(p. M1399L) which was not identified by polyphen-2 and SIFT. Examination of the mutation using 1,000 Genomes provided evidence that the identified sequence variant is a rare polymorphism with a MAF of 0.0022. In addition, the mutation that was identified was in the NC1 (trimeric noncollagenous) domain. It was previously demonstrated that mutations of COL4A3/COL4A4/COL4A5 in the NC1 domain disrupt heterotrimer formation in podocytes and subsequently inhibit secretion into the GBM domain ([@b39-mmr-17-01-1513]). These results indicate that the substitution is pathogenic and may lead to FSGS.

Discussion
==========

In the present study, a Chinese family presenting with GMH, or CKD were investigated. Renal biopsies from the proband and her sister demonstrated FSGS and normal GBM. Her father reached CKD 8 years ago. A genetic analysis was performed on 15 genes associated with FSGS in the proband and her father, and a homozygous m. 3290T\>C missense mutation in TRNL1 was identified in the two siblings. Next generation sequencing of the siblings was performed to reveal a second mutation, a heterozygous c. 4195A\>T missense variant in COL4A4. To the best of the authors knowledge, this is the first report of the two aforementioned mutations that may co-segregate with disease in familial hematuria, histologically characterized by FSGS.

It has been demonstrated that podocyte damage is sufficient to cause FSGS, which results from a number of podocyte-specific gene mutations ([@b7-mmr-17-01-1513]--[@b24-mmr-17-01-1513]). In the present study, Massarray sequencing of 18 podocyte-specific genes in a family including two sisters and their father was performed. In the family, no mutations were identified in the genes most frequently reported including NPHS1, NPHS2, CD2AP, PLCE1, ACTN4, TRPC6, INF2 and WT1.

mtDNA including COQ2 and PDSS2 ([@b18-mmr-17-01-1513]--[@b19-mmr-17-01-1513]), has also been identified to be associated with focal glomerulosclerosis. Human mtDNA which encode subunits of enzyme complexes involved in oxidative energy metabolism may result in various diseases and syndromes and the most severely affected organs are the brain, heart, skeletal muscle, sensory organs and the kidney, in mtDNA associated diseases ([@b40-mmr-17-01-1513]). In recent years, the involvement of the kidney has been concerned in mitochondrial cytopathies by nephrologists. tRNALeu (UUR) gene also called mitochondrial tRNAleucine 1, is a hotspot in mitochondrial disease and has a high incidence of mutations ([@b41-mmr-17-01-1513]). The tRNALeu (UUR) mutation is associated with the mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome. Renal tubular dysfunction and FSGS have been associated with MELAS ([@b42-mmr-17-01-1513],[@b43-mmr-17-01-1513]). It has been reported that the mtDNA mutation may also cause isolated renal disease in patients who were not diagnosed as MELAS ([@b44-mmr-17-01-1513]--[@b46-mmr-17-01-1513]). It was reported by Lowik, *et al* ([@b17-mmr-17-01-1513]) that 3243A-G may be identified in a steroid-resistant nephrotic syndrome with histological signs of FSGS. They concluded that mtDNA abnormalities lead to a steroid-resistant nephrotic syndrome with histological signs of FSGS. In the present study, an mtT3290C mutation in TRNL1 in two siblings was identified. It was first reported by Opdal *et al* ([@b38-mmr-17-01-1513]) that the mtT3290C mutation may serve a role in various patients with the SIDS cases ([@b40-mmr-17-01-1513]).

The T3290C mutation is located in the T ΨC loop of the TRNL1 gene, disrupting the three-dimensional shape of this tRNA. It has been proposed that a common pathogenic mechanism associated with mutations in this particular mtDNA gene may be a decreased steady-state level of tRNALeu (UUR) and a partial impairment of mitochondrial protein synthesis ([@b47-mmr-17-01-1513]). Opdal *et al* ([@b40-mmr-17-01-1513]) proposed that any mtDNA mutation may affect oxidative energy metabolism and thereby induce adenosine triphosphate depletion ([@b40-mmr-17-01-1513]), and m. T3290C mutation may affect the complex structural podocyte composition by affecting metabolic and energy requirements. Hence, there are several reasons to suggest that m. 3290T\>C in TRNL1 gene may be involved in FSGS. In addition, homozygous mutation was identified in the two sisters and their father, whereas mtDNA exhibited maternal inheritance. However, blood from the mother was not available and it is unclear whether these mutations are somatic or inherited. To the best of the authors knowledge, the present study is the first to document the development of FSGS and isolated hematuria with the mitochondrial T3290C transition.

However, the affected cases were in the father\'s pedigree including paternal aunts and paternal cousins, and it were not consistent with typical maternal inheritance.

This suggests that mutations in other genes may also be involved in the development of FSGS. The list of genes implicated in the development of FSGS is updated continuously. The introduction of more comprehensive screening technologies including WES allows simultaneous screens for mutations in other potentially relevant genes and contributes to the detection of novel genes or mutations ([@b48-mmr-17-01-1513],[@b49-mmr-17-01-1513]), instead of testing for one gene at a time, or screening for certain known mutations only.

As the sisters exhibited normal GBMs, the type IV collagen-associated genes were not initially screened. However, using WES technology a single heterozygous mutation c. A4195T (p. M1399L) in the COL4A4 gene, which encodes the α4 chain of type IV collagen, the most important structural component of the GBM, was identified.

Though the variant was not demonstrated by SIFT and polyphen-2, the COL4A4 mutation that was identified in the siblings is most likely disease-causing. Firstly, certain studies suggest that COL4A3 and COL4A4 mutations may cause a wide spectrum of disease phenotypes from AS to FSGS ([@b39-mmr-17-01-1513],[@b50-mmr-17-01-1513],[@b51-mmr-17-01-1513]). Malone *et al* ([@b51-mmr-17-01-1513]) was the first to document COL4A3 and COL4A4 mutations associated with primary FSGS. The authors identified seven variants in COL4A3 and COL4A4 in a cohort of 70 families with a pathological diagnosis of familial FSGS of unknown cause. Notably, each of these variants were heterozygous and no mutations in known FSGS-associated genes were identified ([@b51-mmr-17-01-1513]). The authors hypothesized that mutations in mature GBM collagen (IV) may have a direct role in the pathogenesis of FSGS and that the phenotypes induced by mutations in mature GBM collagen (IV) genes may phenocopy primary FSGS. Secondly, the mutation that was identified in these variants is exhibited at very low frequencies of 0.0022 by 1,000 Genomes. In addition, the mutation is located in the NC1 domain where the variant may disrupt heterotrimer formation in the podocyte and subsequent secretion into the GBM domain ([@b39-mmr-17-01-1513]). Molecular and bioinformatics analyses suggested that the mutations in the conserved glycine-rich regions or in the NC1 carboxy terminus of the involved proteins are deleterious ([@b52-mmr-17-01-1513]). It is now recognized that the mature type IV collagen network, a3a4a5, originates solely in the podocytes ([@b53-mmr-17-01-1513]). Kruegel *et al* ([@b54-mmr-17-01-1513]) proposed that podocyte receptors may recognize the mutated COL4 leading to upregulation of podocyte profibrotic factors, including transforming growth factor-β, connective tissue growth factor and matrix metalloproteinases-2. −9 and −10. These data add support to the hypothesis that these variants may cause disease.

The COL4A4 mutations follow an autosomal dominant or recessive inheritance pattern. The patients with heterozygous mutations in the COL4A3/COL4A4 are more common in the carrier state of atherosclerotic renal artery stenosis and TBMN than autosomal dominant AS, and familial hematuria and GBM morphology are typical clinical features of these diseases ([@b54-mmr-17-01-1513],[@b55-mmr-17-01-1513]). The patients with COL4A4 mutations documented in the present study had significant hematuria at diagnosis. Biopsies in the families in the present study demonstrated the typical signs of FSGS on light microscopy and foot process effacement on EM. However, in the present study there were no consistent GBM ultrastructural alterations in the siblings with COL4A4 variant and there was no decrease in collagen (IV) staining in the GBM. In addition, these phenotypes also lack extra-renal manifestations including deafness or ocular symptoms, which are characteristic of AS. In the two patients, there was not enough supportive evidence that was consistent with AS or TBMN and the sisters were diagnosed as familial hematuria rather than AS or TBMN.

Whether or not the reported heterozygous variant (c4195A\>T) alone in the present study is sufficient to cause FSGS, or is only partially penetrant, the study by Malone *et al* ([@b51-mmr-17-01-1513]) demonstrated that the variants in COL4A3/COL4A4 c may be associated with FSGS, however the possibility of the presence of other modifier genes and/or other acquired factors cannot be excluded ([@b51-mmr-17-01-1513]). These genes or factors may determine the phenotypic heterogeneity that leads to variability in disease progression and results in an unpredictably benign course or long-term progression of hematuria to proteinuria, and ESRD ([@b56-mmr-17-01-1513]). Podocyte foot process effacement was a constant result in the present report, and it suggests that the observed phenotype may be due to podocyte abnormalities. So it is possible that the variable phenotypes demonstrated in the present study may be due to variants in COL4A4 acting as disease modifiers for FSGS and this is consistent with the view of Bullich *et al* ([@b57-mmr-17-01-1513]).

FSGS-associated genes frequently follow an autosomal dominant or recessive inheritance pattern, therefore a mutation in mtDNA may have been overlooked. In addition, the WES cannot be performed to analyze mtDNA mutations. The results of the present study demonstrated that Massarray technology and WES technology were complementary, each with its own advantage. The combination of Massarray technology and WES may improve the detection rate of genetic mutation with an increased level of accuracy.

At present, monogenic FSGS subtypes have been reported by genetic studies primarily focusing on familial FSGS. However, a rare study on the potential role of combinations of mutations in different genes was reported in FSGS ([@b12-mmr-17-01-1513],[@b13-mmr-17-01-1513]). The present study, to the best of the authors knowledge, is the first report to document two relevant genes co-segregated with FSGS.

It has been proposed that hematuria is the forgotten CKD factor ([@b32-mmr-17-01-1513]). In a number of families carrying these mutations, certain members continue to exhibit chronic and isolated MH for the rest of their lives, whereas others develop proteinuria later on in life, usually with hypertension and a variable gradual progression to CRF leading to ESRD ([@b58-mmr-17-01-1513],[@b59-mmr-17-01-1513]).

Therefore, the term familial hematuria (FM) would be appropriate to use instead of misnomer benign familiar hematuria and the pediatric nephrologist must give a correct prediction of prognosis to the children with hematuria and to avoid misdiagnosis. Genetic testing benefits include early diagnosis, highly-targeted therapy and an ESRD onset delay. Genetic investigations may be more definitive and diagnostic than renal biopsies.

For the initial treatment of FSGS, the Kidney Disease Improving Global Outcomes 2012 guideline ([@b60-mmr-17-01-1513]) recommends that corticosteroid and immunosuppressive therapy be considered only in idiopathic FSGS associated with clinical features of nephrotic syndrome ([@b17-mmr-17-01-1513]). There is no evidence to suggest corticosteroids or immunosuppressive therapy in the treatment of the mutation induced FSGS.

The treatment for the two sisters consisted of Chinese traditional medicines including huaiqihuang and shenyansiwei capsules. Regular follow-up surveys were carried out in the clinic. The older sister has had enalapril administered up to this point as proteinuria was detected five months following diagnosis with FH. Currently, the proteinuria is in remission and hematuria is reducing gradually. Blood pressure was relatively well regulated and renal function was normal therefore steroid, and immunosuppressive therapy was not instituted.

The results of the present study demonstrate that it may not be possible to take a detailed three generational family history in every pediatric out-patient clinic, however it is always worth asking if there is a family history of kidney problems, especially if these have occurred in relatively young people. Screening for COL4A mutations in FSGS, particularly when presenting with FH, is recommended.

Whether the variants in COL4A4 were inherited from their father and TRNL1 were inherited from the healthy mother, has not been resolved. Next, the blood of the proband\'s parent and other affected family members should be obtained to screen for COL4A4 and TRNL1 genes. Then, the pathogenic mechanism of two variants should be verified by animal or *in vitro* experiments.

In the present study, the sisters with mtDNA mutation did not manifest features including hearing loss, diabetes mellitus, neuromuscular symptoms or cardiomyopathy. The family members should be followed closely to identify the development of associated conditions including diabetes mellitus and cardiomyopathy.

Heterozygous carriers of COL4A3 or COL4A4 mutations, irrespective of gender, may be asymptomatic, may have hematuria (carriers of recessive disease) or may progress to ESRD ([@b58-mmr-17-01-1513],[@b59-mmr-17-01-1513]). Therefore, the family members require long-term follow-up.

In the present study, a missense mutation in the COL4A4 and TRNL1 genes were identified, which may be responsible for MH with FSGS in this family. Screening for COL4A mutations in familial FSGS patients is recommended. Genetic investigations of families with similar clinical phenotypes should be a priority for nephrologists. The combination of Massarray technology and WES may improve the detection rate of genetic mutation with a high level of accuracy.

The present study was supported partially by the National 'Twelfth Five-Year' Science and Technology Support Project (2012BAI03B02), Ministry of Science and Technology of China, and by Xiangya Excellent Physician Award (ZWY, 2013), Central South University, China.

![Light and electron microscopic images of the renal biopsy taken from the proband. (A) Light microscopy, PASM staining. A glomerulus is exhibited with segmental sclerosis, hyalinosis and adhesion to Bowman\'s capsule, consistent with an FSGS lesion. (B) Light microscopy, PASM staining of the renal tubules and glomeruli. Exhibited is globally sclerotic glomeruli with small arteries demonstrating loss of smooth muscle fibres (arrow). (C) Light microscopy, periodic acid-Schiff staining of the renal biopsy taken from the proband. Exhibited is a glomerulus with segmental sclerosis, hyalinosis (arrow), consistent with an FSGS lesion, vacuolation of the tubular epithelial cells, effacement of the brush border of lumen surface and inflammatory cell infiltration. (D) Electron microscopy of kidney section, (original magnification, ×5,000). Glomerular segment with extensive podocytes foot process effacement. The endothelium was swollen and hypertrophied. The glomerular basement membrane has normal structure and thickness. Electron-dense deposits were observed in the paramesangial regions. Massive tubules with swelling tubular epithelial cells, edema in the interstitium and inflammatory cell infiltration (not shown). FSGS, focal segmental glomerulosclerosis; PASM, Periodic Schiff-Methenamine Silver.](MMR-17-01-1513-g00){#f1-mmr-17-01-1513}

![Pedigree of the presenting family. Multiple family members demonstrated asymptomatic isolated hematuria. Octagons represent females and squares represent males. Shaded, affected; shaded with arrow, proband. Diagonal lines represent family members who died because of other disease.](MMR-17-01-1513-g01){#f2-mmr-17-01-1513}

![Sequence analysis of tRNA leucine 1 in the two affected siblings. Two patients are homozygous for a missense mutation (m.3290T\>C).](MMR-17-01-1513-g02){#f3-mmr-17-01-1513}

###### 

Selected list of 18 genes associated with FSGS syndrome.

  Author, year             Gene                                 Locus      Inheritance            Protein                                                                                          Phenotype                                                                                                                                           (Refs.)
  ------------------------ ------------------------------------ ---------- ---------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
                           SD-associated and adaptor protein:                                                                                                                                                                                                                                                                                          
  Santin, 2009             NPHS1                                19q13.1    AR                     Nephrin                                                                                          CNS/NS, FSGS                                                                                                                                        ([@b7-mmr-17-01-1513])
  Tonna, 2008              NPHS2                                1q25-q31   AR                     Podocin                                                                                          CNS, NS-childhood and adult onset, FSGS                                                                                                             ([@b8-mmr-17-01-1513])
  Gigante, 2009            CD2AP                                6p12.3     AD                     CD2 associated protein                                                                           Early-onset NS, HIV nephropathy, FSGS                                                                                                               ([@b9-mmr-17-01-1513])
  Hinkes, 2006             PLCE1                                10q23.33   AR                     Phospholipase C ε 1                                                                              Early-onset NS, DMS                                                                                                                                 ([@b10-mmr-17-01-1513])
  Santin, 2009             TRPC6                                11q22.1    AD                     Transient receptor potential cation channel subfamily C member 6,                                Adult onset NS, FSGS                                                                                                                                ([@b11-mmr-17-01-1513])
                           Nuclear proteins:                                                                                                                                                                                                                                                                                                           
  Hall, 2013               WT1                                  11p13      Sporadic, AD           Wilms\' tumor 1                                                                                  Adult onset NS, Denys-Drash and Frasier Syndromes, DMS, FSGS                                                                                        ([@b12-mmr-17-01-1513])
  Boyer, 2013              LMX1B                                9q34.1     AR                     LIM homeobox transcription factor 1, β                                                           Nail-Patella Syndrome/NS only,                                                                                                                      ([@b13-mmr-17-01-1513])
  Boerkoel, 2002           SMARCAL1                             2q34-q36   AR                     SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-like 1   Schimke immuno-osseous dysplasia (syndromic immune complex nephritis)                                                                               ([@b14-mmr-17-01-1513])
                           Actin cytoskeleton and signaling                                                                                                                                                                                                                                                                                            
  Choi, 2008               ACTN4                                19q13      AD                     α-actinin 4                                                                                      Adult onset NS, FSGS                                                                                                                                ([@b15-mmr-17-01-1513])
  Gbadegesin, 2011         INF2                                 14q32      AD                     Inverted formin 2                                                                                Familial/sporadic NS; Charcot-Marie-Tooth, FSGS                                                                                                     ([@b16-mmr-17-01-1513])
  Lowik, 2005              Mitochondrial                                                                                                                                                                                                                                                                                                               
                           MTTL1                                mtDNA      Maternal inheritance   tRNA-LEU                                                                                         MELAS syndrome; NS ± deafness and diabetes                                                                                                          ([@b17-mmr-17-01-1513])
  Diomedi-Camassei, 2007   COQ2                                 4q21.23    AR                     Coenzyme Q2 4-hydroxybenzoate polyprenyltransferase                                              Mitochondrial disease/isolated nephropathy                                                                                                          ([@b18-mmr-17-01-1513])
  Lopez, 2006              PDSS2 GBM                            6q21       AR                     Prenyl diphosphate synthase subunit 2                                                            Leigh syndrome, FSGS or collapsing glomerulopathy                                                                                                   ([@b19-mmr-17-01-1513])
  Matejas, 2010            LAMB2                                3p21       AR                     Laminin β 2                                                                                      Pierson syndrome: CNS with ocular abnormalities, isolated early-onset NS, DMS FSGS                                                                  ([@b20-mmr-17-01-1513])
  Hatei, 2005              LAMB3                                1q32       AR                     Laminin β 3                                                                                      Epidermolysis bullosa, junctional, non-herlitz type, somatic mosaic revertant, Junctional epidermolysis bullosa gravis of Herlitz                   ([@b21-mmr-17-01-1513])
  Kambham, 2000            ITGB4                                17q25      AR                     β4-integrin                                                                                      NEP syndrome-NS, epidermolysis bullosa and pulmonary disease                                                                                        ([@b22-mmr-17-01-1513])
                           Other-Metabolic or lysosomal                                                                                                                                                                                                                                                                                                
  Berkovic, 2008           SCARB2 (lysosomal)                   4q21.1     AR                     Scavenger receptor class B member 2                                                              Nephrotic syndrome, nephrotic syndrome with C1q deposits, progressive myoclonic epilepsy (Action myoclonus renal failure syndrome ± hearing loss)   ([@b23-mmr-17-01-1513])
  Serebrinsky, 2015        GLA                                  Xq22.1     XLR                    α-galactosidase A                                                                                Andeson-Fabry disease                                                                                                                               ([@b24-mmr-17-01-1513])

AR, autosomal recessive; AD, autosomal dominant; XLR, X-linked recessive; CNS, central nervous system; FSGS, focal segmental glomerulosclerosis; NS, nephrotic syndrome; NEP, nephrotic syndrome; DMS, diffuse mesangial sclerosis; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; HIV, human immunodeficiency virus; GBM, glomerular basement membrane; NPHS1, nephrin; NPHS2, podocin; CD2AP, CD2 associated protein; PLCE1, phospholipase C ε; ACTN4, actinin α 4; TRPC6, transient receptor potential cation channel subfamily C member 6; INF2, inverted formin, FH2 and WH2 domain containing; WT1, Wilms tumor 1; LMX1B, LIM homeobox transcription factor 1β; LAMB, laminin subunit β; GLA, galactosidase a; ITGB4, integrin subunit β 4; SCARB2, scavenger receptor class B member 2; SD, slit diaphragm of podocytes; COQ2, coenzyme Q2; PDSS2, decaprenyl diphosphate synthase subunit 2; UUA/G; *TRNL1*, mitochondrially encoded tRNA leucine 1; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1; GLA, galactosidase.

###### 

Primer combinations for the 138 mutations used in the multiplex assays

  WELL   SNP_ID          5′ PCR primer                     3′ PCR primer                     UEP_SEQ
  ------ --------------- --------------------------------- --------------------------------- -------------------------------
  W1     rs121912602     ACGTTGGATGGTCTTGAGGATCAGAACCAC    ACGTTGGATGATGAGATGGCAACCCGAAAG    AACCACTCCGGCTTC
  W1     rs121918233     ACGTTGGATGGGAAAACAACCTGGTTCAGC    ACGTTGGATGTTGCTTAGGAACCTGGCTTC    GCTGCCAAACCAATG
  W1     rs28935493      ACGTTGGATGGTTTATCATAGCTACAGCCC    ACGTTGGATGAGGGAGACAACTTTGAAGTG    AAGCCTGAGAGAGGT
  W1     rs121912489     ACGTTGGATGCCCAGGTACTTGATATTTCC    ACGTTGGATGTGTCCGTACCAGCTTCAGAT    AGCCTGGTATCTCCTA
  W1     rs121912462     ACGTTGGATGAGATGTAGCTCTCATCTCCC    ACGTTGGATGTCCAACCAGGCTCACACACA    ccTCCCTCTCTGCAGAC
  W1     rs121918231     ACGTTGGATGAGTTGAAATGTCTCCAGCGG    ACGTTGGATGACATGAAGCTAAGGTATCTG    ccCCAGCGGCTATTGGA
  W1     rs80356680      ACGTTGGATGACCTGCTTGTTGGGAGGAC     ACGTTGGATGTACTGGGTGCAGTAGGTCTC    GGAGGACCCGGTTTCTC
  W1     rs121434393     ACGTTGGATGTCTGCGTTCAACTCACCTTC    ACGTTGGATGAAGATATGTACTGCAGGCCC    TCACTTCATCACTCTCCT
  W1     rs121912490     ACGTTGGATGATCTGGCAATGTGAGTGGAG    ACGTTGGATGTTGGGTCACGGTAGAAGAAG    TGTGAGTGGAGGTGTGTG
  W1     rs28941777      ACGTTGGATGCTTCTCTGTCCATTTAGGTG    ACGTTGGATGTATGAGTCCTGGTGTGGGTC    CCATTTAGGTGTGAAACCA
  W1     rs119473037     ACGTTGGATGCTGCTGGAGGAAGCAGTCAT    ACGTTGGATGGCAATCACCACTATCTTGCG    tgacGCAGTCATGCTGCGG
  W1     rs28935485      ACGTTGGATGTCCTCCTCTCTTGTTTGAAT    ACGTTGGATGCAGAGGGCCATCTGAGTTA     ggtggGGCCTCAGCTGGAAT
  W1     rs118203956     ACGTTGGATGATGGAAACAAGGCACTGGAG    ACGTTGGATGAATCTGGTCACAGCAAACAC    cccgGGAGAGCTTTCCTCCCT
  W1     rs121909119     ACGTTGGATGGAGATATCGGGCCTGAAAAC    ACGTTGGATGTGTGACTCACACAGTTGACG    AAGATTTCATCTTTGTAGCCC
  W1     rs267606710     ACGTTGGATGGTTTTTAGGAAAGAACTGG     ACGTTGGATGCCTCTAGATTACTTCTCATTG   AGGAAAGAACTGGAAAAACTG
  W1     rs28939695      ACGTTGGATGTTCCTCTCCCCGCCAGATCC    ACGTTGGATGAAACACACCAGCCTCACCC     gactGCCCAGAAACTGTGGATT
  W1     rs267606955     ACGTTGGATGCAATTGTCAGGTTGGTGTAG    ACGTTGGATGTTGATGTCTATGCAGTGCCC    ggggaTGACTCGGAGCCAGATC
  W1     rs28935490      ACGTTGGATGCCTGATTGATGGCAATTACG    ACGTTGGATGACATCAGCCCTCAAGCCAAA    ccctATGGCAATTACGTCCTTAT
  W1     rs104894841     ACGTTGGATGCAGGAATCATCAATGTCAGC    ACGTTGGATGTATCTGTTTTCACAGCCCA     ATCATCAATGTCAGCAAAATTTC
  W1     rs121912466     ACGTTGGATGGATAAAGAGGGGCACCCGTA    ACGTTGGATGACCTCTGACCACCTCCGAAC    cccCCCTCCTGGAACTCCACCATG
  W1     rs121912461     ACGTTGGATGTGCTGTCCTCCACTCTGGC     ACGTTGGATGACTCCATGTCCGATGATCTG    atcccCTCTGGCCCTGCCGTACCC
  W1     rs121907904     ACGTTGGATGTGCTGTGCATCTGTAAGTGG    ACGTTGGATGTCTGAGACCAGTGAGAAACG    GACAGCTTAAAATATCTCTTATTG
  W1     rs199474665     ACGTTGGATGGCCCGGTAATCGCATAAAAC    ACGTTGGATGGTTGGCCATGGGTATGTTGT    caaaaTTTACAGTCAGAGGTTCAA
  W1     rs118203955     ACGTTGGATGAAGACCAGTGACTCCATGAC    ACGTTGGATGATCCACAAATCTCTTCCAAG    cccaTCAGCTCCTGTAGTCTTACAT
  W1     rs74315344      ACGTTGGATGCCTTTGCCCTCTTGTTCTCC    ACGTTGGATGAGCTCTGAGGATGGAGAGGA    aaacGCCCTCTTGTTCTCCTTGTGC
  W1     rs121912603     ACGTTGGATGGCTTTCTTTATCCTCTTTGGG   ACGTTGGATGAACATTCTGGAAGACAGACC    TGGGATTTCTTCATTATATTCAAACT
  W1     rs121912482     ACGTTGGATGGGGATTCCAGCAACTCAAAG    ACGTTGGATGCCCATAGTTCCATGGACAAG    aagaAACTCAAAGTCAAAAAATTCAA
  W1     rs121912488     ACGTTGGATGTTGTCTCCCAACGTGTGTAG    ACGTTGGATGCAGACCTGTTGAAGATCACC    ggtagGTAGACGAGTCAGGTTCACCC
  W1     rs121912485     ACGTTGGATGCAATGTCCTGCTTGGTCTGG    ACGTTGGATGTACTGTTCTGCAGAAGATG     ggTGGGGAGCCTGGCTGCAATGGCCT
  W1     rs80356681      ACGTTGGATGACCCTCCCAGCGCCTACTAT    ACGTTGGATGTCAGCATGGCCGTGACAGAA    cccaaCAGCGCCTACTATGCTGTGTCC
  W1     rs121912605     ACGTTGGATGGTTGAAGCCATTGATCGCAG    ACGTTGGATGTCGTTGCTGAGGCAATGAAC    gtccACTCTGACCTGCCAATCATCATAT
  W1     rs74315347      ACGTTGGATGAAGGAGCCCAAGAATCAAGC    ACGTTGGATGAGCAAATGGCATCTATCTCC    ctcagCCAAACTTTTTTCTGCCTAGATC
  W1     rs267606954     ACGTTGGATGTACAGAATCTCCTGACTAAC    ACGTTGGATGGATGATGTAGAAGAAGACGC    catAATCTCCTGACTAACAAAGTGGATC
  W1     rs121918232     ACGTTGGATGTTCTCCATTTCAAAGGAGAG    ACGTTGGATGTGGCACTGGGTGTTCTTCTG    tggacAACGTTTAATATACCTGTAGTAA
  W1     rs74315343      ACGTTGGATGGGTTGTACAAGAGTATGAAAG   ACGTTGGATGGAGTGTTTTTTTACCAGGGC    cCAAGAGTATGAAAGAGTA ATTATATTC
  W2     rs119473038     ACGTTGGATGAAGAGGGTGATCCTGTTGTC    ACGTTGGATGAGAAAGTTGGCTTGACTGCG    ACACCAGCCATGTCC
  W2     rs119473035     ACGTTGGATGCAGAGCTGAGAAGTTATTGG    ACGTTGGATGTTTGGGATGGGCCTTGCTTG    TTGGCAGAACAGCAT
  W2     rs121434390     ACGTTGGATGGTTAACGTTGAGTGAGTGGC    ACGTTGGATGGGAACGCTTTTTGGATGCAG    aATCTTCCGCACCACT
  W2     rs119473033     ACGTTGGATGAGCTCATTTCTCCCCAACAG    ACGTTGGATGAATTGGTCTCAGAAAGCCCG    ACAGGCCCCTGATTCAA
  W2     rs104894835     ACGTTGGATGTTGCACATGAAGCGCTCCCA    ACGTTGGATGCCTCGTTTCCTGGGACATC     ctaGTCCTTGCCAATCCA
  W2     rs74315346      ACGTTGGATGATCTCCAGAGTTTGGAGACG    ACGTTGGATGCTCCTCCTCTCTTTTAGGTC    TCAACCTTGTGGTAGGTA
  W2     rs121912601     ACGTTGGATGTTCAGGCATTACCTTTCAGC    ACGTTGGATGGTCTTTGGGAGCAAGAAGTG    TTACCTTTCAGCATCATTC
  W2     rs121907909     ACGTTGGATGCTTCTCTGTCCATTTAGGTG    ACGTTGGATGTATGAGTCCTGGTGTGGGTC    CCAGTGTAAAACTTGTCAG
  W2     rs2071225       ACGTTGGATGGATGTAGTTCTGGGTTCCTC    ACGTTGGATGTTAAAAGCCCAGGTTACCCG    gaatCTGCATTGTCACGGT
  W2     rs121907908     ACGTTGGATGAGAGGATGGGCGTTGTGTG     ACGTTGGATGAGCCACACTGAGCCTTTTTC    gggGTTGTGTGGTTATCGC
  W2     rs61747728      ACGTTGGATGAACCACTATGAAGCGTCTCC    ACGTTGGATGCTAAGTACCTTTGCATCTTG    taatCGTCTCCTAGCACATC
  W2     rs2717-192515   ACGTTGGATGTTCTGGGCTCACTATCTCAC    ACGTTGGATGGCAGAAGCATTGTGTACTCC    gAAGGGCCACATATAAAGAG
  W2     rs104894837     ACGTTGGATGATGTCGTAGTATCCAAAAC     ACGTTGGATGAGCAAAGGACTGAAGCTAGG    CGTAGTATCCAAAACTCCCAG
  W2     rs2717-192520   ACGTTGGATGCTGGTCCAGCAACATCAACA    ACGTTGGATGGCTGACATTGATGATTCCTG    CTGGTTAAAAGATGTCCAGTC
  W2     rs121912492     ACGTTGGATGTGCAAACACAACACACGTGG    ACGTTGGATGGCAGGTCACGATAGAAATCC    ccaccACACACGTGGCCTCAAC
  W2     rs28935197      ACGTTGGATGGAATCATCAATGTCAGCAAAA   ACGTTGGATGGAAAGTAAACAGAAGAGTC     gaACTGTCGGATTTCTGTATAA
  W2     rs121909118     ACGTTGGATGCTTACATCCTAACAGGTCAG    ACGTTGGATGTCTGCAGGAACTTTATACCG    TTTCAGTGACTATGAGAGTGTA
  W2     rs28935492      ACGTTGGATGCTCTTATTTACCTGTCTAAGC   ACGTTGGATGATTGCCATCAATCAGGACCC    catcTACCTGTCTAAGCTGGTAC
  W2     rs267607207     ACGTTGGATGATCGGACAGAGGCACTGATG    ACGTTGGATGAGAGAGCTTGCCAAGTGCC     ggggaTCAGAAGGAGGACTTCAA
  W2     rs28942089      ACGTTGGATGCCAGCAATGAGAAGTGAACC    ACGTTGGATGTTCAGACCAGCTCAAAAGAC    ctAAGTGAACCTACAAACCTGTAT
  W2     rs267606919     ACGTTGGATGGACGCAGGAGGAGGTGTCT     ACGTTGGATGGGTACCTCTGAGTGAGGGAA    actCAGGAGGAGGTGTCTTATTCC
  W2     rs199474663     ACGTTGGATGTTGTTAAGATGGCAGAGCCC    ACGTTGGATGAGAGGAATTGAACCTCTGAC    ttggtAGAGCCCGGTAATCGCATA
  W2     rs267607183     ACGTTGGATGGCAGGTGCTTACCGATAAAC    ACGTTGGATGCAACGCCGTCATCTTGGG      ccttTGCTTACCGATAAACTCGTTC
  W2     rs121909486     ACGTTGGATGAGACACTGGCAGCTGAGAC     ACGTTGGATGGGTGGCCTCTTACCTTTGC     gcggGGTCCAGGTCTGGTTTCAGAA
  W2     rs121912487     ACGTTGGATGCTCTGTAGGTCCAACT TAAC   ACGTTGGATGGAGAAGTAACCACA CTGACC   cccctATTCCAGCAACTCAAA GTCAA
  W2     rs104894834     ACGTTGGATGCCCAAAGAGATT CAGAAGGC   ACGTTGGATGACATAATTAGCTAGC TGGCG   aagtCAGACTTCAGGCAGACCCT CAG
  W2     rs121912467     ACGTTGGATGTTCACCGTGTAG CGGTAGG    ACGTTGGATGTTGGGCCCATGAAGA AAGTG   gggccGGTTCTCAATAAGCAGC ATCC
  W2     rs2717-192517   ACGTTGGATGCCCTCTGTCCATTCATTCTT    ACGTTGGATGGGAGACATGGTAACAAGTCA    ccTTAACCTGTTTAATTTTCTTCTCAG
  W2     rs121907911     ACGTTGGATGAGTTCACTGGCACAGCCGGA    ACGTTGGATGTTAGGAAACATCCTGGCCTG    gacgGGCACAGCCGGAGCCTGTCGCTA
  W2     rs121907911     ACGTTGGATGAGTTCACTGGCACAGCCGGA    ACGTTGGATGTTAGGAAACATCCTGGCCTG    gacgGGCACAGCCGGAGCCTGTCGCTA
  W2     rs121434394     ACGTTGGATGGGAAATTAAGCAGGACATCTC   ACGTTGGATGAAGTTCTGCTAGGTCTTCTG    ctcccTTAAGCAGGACATCTCAAGTCTC
  W2     rs28935488      ACGTTGGATGGTTTCCTCCTCTCTTGTTTG    ACGTTGGATGAGGGCCATCTGAGTTACTTG    gcATTATTTCATTCTTTTTCTCAGTTAG
  W2     rs121912465     ACGTTGGATGAGCAAACCGCTGCAAGAAGG    ACGTTGGATGAGTAGGCGCAGTCCTTATCC    ccgtTGCAAGAAGGCCCCAGTGAAGAGC
  W2     rs80356682      ACGTTGGATGCCGGATCCTAGATGCAAAGA    ACGTTGGATGACCTCCTGCTCTGTGACTG     ctcgGCAAAGAGTAAGATTGAGCAGATC
  W3     rs104894836     ACGTTGGATGTGATGCAGGAATCTGGCTCT    ACGTTGGATGTGCACTGGGAGCGCTTCAT     CTGGCTCTTCCTGGC
  W3     rs104894849     ACGTTGGATGTTACAGGCCACTCCTTTACC    ACGTTGGATGGGGCTGTAGCTATGATAAAC    AGCAACTGCGATGGT
  W3     rs267607208     ACGTTGGATGTTATGTCTGTCAGGCTCAGG    ACGTTGGATGGGAGGACTTCAACAGCAAAC    GGGTATGGGCAGAGA
  W3     rs28935196      ACGTTGGATGTGGGAGTTTTGGATACTACG    ACGTTGGATGCTGTCACAGTAACAACCATC    CCAGACCTTTGCTGAC
  W3     rs104894847     ACGTTGGATGAGAACTACATCTGGGCTGCG    ACGTTGGATGTGCTCTAGCCCCAGGGATGT    cTGCGCTTCGCTTCCTG
  W3     rs121907905     ACGTTGGATGTCTTCCCCAAGGTGAGAAAC    ACGTTGGATGTGTCTTTTGAGCTGGTCTG     AGTGTGACTTCAAGGAC
  W3     rs104894833     ACGTTGGATGAGACCATGAGCTCTGCCATC    ACGTTGGATGTGGGAGGTACCTAAGTGTTC    TCTCCATGAAGAGCTTCT
  W3     rs104894838     ACGTTGGATGTCTCATACAGGTTATAAGC     ACGTTGGATGAAGGGCCACATATAAAGAGG    AAGCATTGTGTACTCCTG
  W3     rs121909489     ACGTTGGATGTTCCTGATGCGAGTCAACGA    ACGTTGGATGAAGTAGCAGCTGGTGGTGAG    TGGCACGAGGAGTGTTTG
  W3     rs121909491     ACGTTGGATGTTGAAGGCTCTTCGCTGCTG    ACGTTGGATGAGTCAGAGCAAGGGCAGCG     gGCGTGGTGAGGATGGTC
  W3     rs137853042     ACGTTGGATGACTGGCTCTCCTCATATTCG    ACGTTGGATGCACCTTCATCCTGGAAGGTC    aTCATATTCGTTCCTGACTC
  W3     rs80338755      ACGTTGGATGTCTCCATGACCACGATGCTC    ACGTTGGATGTTCTGGCCAGATGTTCAGGG    ctaaCTCCGCCTGGGTGTTG
  W3     rs199474668     ACGTTGGATGTTGAACCTCTGACTGTAAAG    ACGTTGGATGGTATTATACCCACACCCACC    tgTTATGCGATTACCGGGCT
  W3     rs267606918     ACGTTGGATGGCGCTTACCAGTGCATTGTG    ACGTTGGATGCCCACATCTGACAACAAGAC    AGTGCATTGTGGACAATGGG
  W3     rs119473034     ACGTTGGATGCTTGCCTCTTACAGAGGAGC    ACGTTGGATGATAACTTCTCAGCTCTGCGG    AGGAAAAAGATTGAAGAGAAT
  W3     rs121912491     ACGTTGGATGCAGACCTGTTGAAGATCACC    ACGTTGGATGTTGTCTCCCAACGTGTGTAG    ccccTGAAGATCACCAACCTAC
  W3     rs2717-192513   ACGTTGGATGCAGTCCTCTGAATGAACAAG    ACGTTGGATGAGACTTCAGGCAGACCCTCA    cctcCATAATTAGCTAGCTGGC
  W3     rs121434392     ACGTTGGATGAGACAATGACAGGTAAGCCG    ACGTTGGATGAGAAACAGAAGCATGACTCG    TAGGCATTAATCCTAGATCTGG
  W3     rs199474660     ACGTTGGATGACAGTCAGAGGTTCAATTCC    ACGTTGGATGTGGGTACAATGAGGAGTAGG    AGAGGTTCAATTCCTCTTCTTAA
  W3     rs267606879     ACGTTGGATGTACCGATAAACTCGTTCCGC    ACGTTGGATGTGATCAACGCCGTCATCTTG    ggaaaTCGTTCCGCAGCTGGGTG
  W3     rs2717-192524   ACGTTGGATGTATTTACCTGTCTAAGCTGG    ACGTTGGATGTCAAGCCAAAGCTCTCCTTC    ccctTCCTGATTGATGGCAATTAC
  W3     rs121918230     ACGTTGGATGCTGTGATCCATCTGTTTGCC    ACGTTGGATGAATTTCTTTACCTGATGGGC    CTGGAGTTATGTGGACACTAATAT
  W3     rs104894842     ACGTTGGATGGGGCCACTTATCACTAGTTG    ACGTTGGATGCAGGCTAAGCCTGAGAGAG     gaAGGGAGACAACTTTGAAGTGTG
  W3     rs121909488     ACGTTGGATGAGGTGGTACACGCACTCCAG    ACGTTGGATGTGTGCATCCGCAGGCTCTTC    cccgtTGGGGGCGATCTTCTCCATG
  W3     rs121912486     ACGTTGGATGGAGAAGTAACCACACTGACC    ACGTTGGATGCTCTGTAGGTCCAACTTAAC    gttgTGACTTTGAGTTGCTGGAATC
  W3     rs104894844     ACGTTGGATGCTTCATCACACAGCTCCTCC    ACGTTGGATGATGTGACTTCTTAACCTTG     ggtggAAAGGAAGCTAGGGTTCTAT
  W3     rs119473036     ACGTTGGATGAGTACTTAAAGACTTTGCC     ACGTTGGATGTGACCTTCTTAGCAAGTTGG    ggacAGACTTTGCCAAGTTTCTTACA
  W3     rs267606953     ACGTTGGATGGAATGACATCCTGTGCAGTG    ACGTTGGATGCCAAGTGCATGATGTTTCTC    gacgaGGGGTGCTTTGATGACTGTTC
  W3     rs74315345      ACGTTGGATGATCTGACGCCCCTTAGTTAC    ACGTTGGATGTGGTGGCGCTGTTGGAGAG     tatCAGATAGTGGTGCTGAATCCGTAC
  W4     rs121909490     ACGTTGGATGAAGCGACCCCGGACCATCCT    ACGTTGGATGACCTCGAAGGAGGCCTTGAA    CTCACCACGCAGCAG
  W4     rs104894848     ACGTTGGATGGCTTCATGTGCAACCTTGAC    ACGTTGGATGACACATGGAAAAGCAAAGGG    CCAGATTCCTGCATCA
  W4     rs199474659     ACGTTGGATGTTGTTAAGATGGCAGAGCCC    ACGTTGGATGAGAGGAATTGAACCTCTGAC    tAGAGCCCGGTAATCG
  W4     rs121912468     ACGTTGGATGTGGAGGAGACGACATTGAAG    ACGTTGGATGACAGCACTCTTCCTGTATTC    GACATTGAAGGCCAGA
  W4     rs267607071     ACGTTGGATGTCTCCGACAGTTGGAACTGC    ACGTTGGATGACATCCGCATCGATGGCTC     tCTGGCACAGGTCCTCC
  W4     rs142059681     ACGTTGGATGCGATAACCACACAACGCCC     ACGTTGGATGACCTGAATGCCTCTGAAGAC    CACACAACGCCCATCCTC
  W4     rs121907907     ACGTTGGATGACCAGTGTGACTTCAAGGAC    ACGTTGGATGGAAGTGAACCTACAAACCTG    AGACCAGCTCAAAAGACA
  W4     rs121912484     ACGTTGGATGCCACGGTCCTCCAGCCCAG     ACGTTGGATGATGCGGACCTCCGGGAGCAG    cccaCAGCCCAGGCCCTGA
  W4     rs121912463     ACGTTGGATGACAGCTTGGGCCTGTCCAAC    ACGTTGGATGTCTCATCTCCCTTCCTTGTC    tAACCAGGCTCACACACAC
  W4     rs104894851     ACGTTGGATGTATCTGTTTTCACAGCCCA     ACGTTGGATGCAGGAATCATCAATGTCAGC    ATACAGAAATCCGACAGTA
  W4     rs74315348      ACGTTGGATGCTGAAGCGCAAAGACAAGCC    ACGTTGGATGACGAGCAGGCCTTCCTAAAG    gaAAAGACAAGCCAAAGTG
  W4     rs121908415     ACGTTGGATGCCCTTGTTGTTCACTTGCAG    ACGTTGGATGAAAGGCATGGTAGAAGCTGG    ggaaGGCCCGGCCCGACGAG
  W4     rs121912604     ACGTTGGATGTTCTGTGGGACAAGAACTGC    ACGTTGGATGATCCATGCTGTCCAGATCTC    caccAGAACTGCCCCATGTAT
  W4     rs121434391     ACGTTGGATGAGAAGCAAAGCATCCCCAAC    ACGTTGGATGGAATGCCCTACAGTTGGCAG    TCTGTAATTTCCAGATGCTCA
  W4     rs28935487      ACGTTGGATGTTGAACAAGGAGGGCTCAAG    ACGTTGGATGCCAGGAGAGAATTGTTGATG    GAGGGCTCAAGTTTTTACCATA
  W4     rs104894852     ACGTTGGATGCTTCAAGGTTAAGAAGTCAC    ACGTTGGATGCTGCATTGTATTTTCTAGCTG   ctTTAAGAAGTCACATAAATCCC
  W4     rs104894827     ACGTTGGATGTAGCCTGGGCTGTAGCTATG    ACGTTGGATGTTACAGGCCACTCCTTTACC    ggttGGCTGTAGCTATGATAAAC
  W5     rs2717-192514   ACGTTGGATGGAGGAACCCAGAACTACATC    ACGTTGGATGAGGGATGTCCCAGGAAACGA    CTGCGCGCTTGCGCT
  W5     rs267606880     ACGTTGGATGCGGAGTAGTTGACCACAGAG    ACGTTGGATGACGGAGGCCAACCTGGAGA     ACAGAGGGCATCTGG
  W5     rs2717-192511   ACGTTGGATGCTAGCTTCCTTTTCACAGGG    ACGTTGGATGAGTTGCTTCCCTGGGTAAAG    ACAGGGAGGAGCTGTG
  W5     rs2717-192516   ACGTTGGATGGCAGAAGCATTGTGTACTCC    ACGTTGGATGCAGTTCTATTGGATTCTGGG    CCCTTTCAAAAGGTGAG
  W5     rs121909487     ACGTTGGATGTTGAAGGCTCTTCGCTGCTG    ACGTTGGATGAGTCAGAGCAAGGGCAGCG     GAGGATGGTCCGGGGTC
  W5     rs28935495      ACGTTGGATGAGGGCCATCTGAGTTACTTG    ACGTTGGATGGTTTCCTCCTCTCTTGTTTG    ataCAGCTGAGGCCAAAG
  W5     rs2717-192521   ACGTTGGATGATAGGAAACAAGCCTACCGC    ACGTTGGATGGTTGATGTTGCTGGACCAGG    GGGTCTTGAACAAGGAGG
  W5     rs104894845     ACGTTGGATGAGCAAAGGACTGAAGCTAGG    ACGTTGGATGTCGTAGTATCCAAAACTCCC    ATGTTGGAAATAAAACCTGC
  W5     rs28941778      ACGTTGGATGTATGAGTCCTGGTGTGGGTC    ACGTTGGATGCTTCTCTGTCCATTTAGGTG    gtTGTGGGTCTTCAGGTGGT
  W5     rs121908417     ACGTTGGATGCTCCTGAAAAGGCATGGTAG    ACGTTGGATGCTTGTTGTTCACTTGCAGAC    gggcGGCATGGTAGAAGCTGG
  W5     rs121907910     ACGTTGGATGGAAGTGAACCTACAAACCTG    ACGTTGGATGACCAGTGTGACTTCAAGGAC    ccctTTTTGAGCTGGTCTGAAC
  W5     rs121434395     ACGTTGGATGAAGTTCTGCTAGGTCTTCTG    ACGTTGGATGAGCAGGACATCTCAAGTCTC    TGAGATTTTTCTTCAAGGAGTT
  W5     rs104894843     ACGTTGGATGGTTTATCATAGCTACAGCCC    ACGTTGGATGAGGGAGACAACTTTGAAGTG    caaaCTAAGCCTGAGAGAGGTC
  W5     rs2717-367202   ACGTTGGATGGCTGACATTGATGATTCCTG    ACGTTGGATGCTGGTCCAGCAACATCAACA    gTTCCTGGAAAAGTATAAAGAGT
  W5     rs199474658     ACGTTGGATGGCCCGGTAATCGCATAAAAC    ACGTTGGATGGTTGGCCATGGGTATGTTGT    aGGTAATCGCATAAAACTTAAAAC
  W5     rs104894828     ACGTTGGATGTGAAGGAGAGCTTTGGCTTG    ACGTTGGATGCAAGTAACTCAGATGGCCCT    gatgTGGCTTGAGGGCTGATGTGT
  W6     rs121912483     ACGTTGGATGACTGGCACCGAACATCCTG     ACGTTGGATGACCTGGCGAGTGTACCAGTA    CATCCTGCCAGCTCT
  W6     rs2717-192510   ACGTTGGATGTTACAGGCCACTCCTTTACC    ACGTTGGATGGGGCTGTAGCTATGATAAAC    CCAGGGAAGCAACTG
  W6     rs121907902     ACGTTGGATGTATGAGTCCTGGTGTGGGTC    ACGTTGGATGCTTCTCTGTCCATTTAGGTG    TGGGTCTTCAGGTGG
  W6     rs121909492     ACGTTGGATGTTCTGAAACCAGACCTGGAC    ACGTTGGATGACCTGTTCCCCTCTCTCTGA    GCTGCCAGTGTCTCTC
  W6     rs151195362     ACGTTGGATGTCAAGCCAAAGCTCTCCTTC    ACGTTGGATGTATTTACCTGTCTAAGCTGG    CAGGACCCCTTGGGCAA
  W6     rs2717-192522   ACGTTGGATGCGCAGCCCAGATGTAGTTCT    ACGTTGGATGTTAAAAGCCCAGGTTACCCG    acGTAGTTCTGGGTTCCTC
  W6     rs2717-192519   ACGTTGGATGGCTGACATTGATGATTCCTG    ACGTTGGATGCTGGTCCAGCAACATCAACA    TTGATGATTCCTGGAAAAG
  W6     rs199474661     ACGTTGGATGAGAGGAATTGAACCTCTGAC    ACGTTGGATGACAGGGTTTGTTAAGATGGC    GTAAAGTTTTAAGTTTTATGCGA

###### 

Analysis of overall quality of the assay.

  Class             Count   Percentage, %
  ----------------- ------- ---------------
  Conservative      5,140   90.84
  Moderate          363     6.42
  Aggressive        47      0.83
  Low possibility   100     1.77
  Bad spectrum      8       0.14
  Total             5,658   100
